Cellenkos

Cellenkos, Inc., headquartered in Houston, Texas, is a clinical-stage biotechnology company focused on developing and commercializing transformative novel allogeneic Treg cell therapies for the treatment of autoimmune and inflammatory diseases. Cellenkos’ proprietary CRANETM platform generates tissue-directed, activated, and enriched Treg cells that leverage cellular intelligence to find, localize, proliferate, and resolve tissue inflammation. Cellenkos boasts a robust pipeline addressing unmet needs in the fields of inflammatory and autoimmune diseases. Safety and early efficacy data of CK0801 for treating aplastic anemia and other cytopenias (NCT03773393) will be presented at the American Society of Hematology (ASH) Annual Meeting on December 13, 2021. Cellenkos has completed a multicenter, placebo-controlled, randomized, double-blind clinical trial (NCT04468971) of CK0802 for treating acute respiratory distress syndrome triggered by COVID-19 (CoV-ARDS). The results will be orally presented at the ASH Annual Meeting on December 13, 2021.